Blood viscosity of COVID-19 patient: a preliminary report
Beuy Joob, Viroj Wiwanitkit

Опубликована: Фев. 15, 2021

COVID-19 is the important global problem. This new coronavirus can cause several hematological changes. Thrombosis a problem might occur in COVID-19. In COVID-19, thrombosis be result of endothelial dysfunction, platelet activation, increasd blood viscosity, and flow disturbance. The change viscosity patients with possible but little mentioned. Here, authors report on preliminary data assessment among 41 patients. According to estimation, estimated values are 72.4 ± 18.6 18.2 2.2 for high low shear rates. Based this report, increased detected patient it associated thrombohemostatic

Язык: Английский

New‐onset autoimmune phenomena post‐COVID‐19 vaccination DOI Open Access
Yue Chen, Zhiwei Xu, Peng Wang

и другие.

Immunology, Год журнала: 2021, Номер 165(4), С. 386 - 401

Опубликована: Дек. 27, 2021

Abstract Coronavirus disease 2019 (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to an unprecedented setback for global economy and health. Vaccination is one of the most effective interventions substantially reduce death due SARS‐CoV‐2 infection. programmes are being rolled out globally, but these vaccines have been approved without extensive studies on their side‐effects efficacy. Recently, new‐onset autoimmune phenomena after COVID‐19 vaccination reported increasingly (e.g. immune thrombotic thrombocytopenia, liver diseases, Guillain–Barré syndrome, IgA nephropathy, rheumatoid arthritis systemic lupus erythematosus). Molecular mimicry, production particular autoantibodies role certain vaccine adjuvants seem be substantial contributors phenomena. However, whether association between manifestations coincidental or causal remains elucidated. Here, we summarize emerging evidence about occurring in response vaccines. Although information pertaining risk as a consequence controversial, merely propose our current understanding associated with vaccine. In fact, do not aim disavow overwhelming benefits mass preventing morbidity mortality. These reports could help guide clinical assessment management vaccination.

Язык: Английский

Процитировано

445

Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19 DOI Creative Commons
Felice D’Agnillo, Kathie‐Anne Walters,

Yongli Xiao

и другие.

Science Translational Medicine, Год журнала: 2021, Номер 13(620)

Опубликована: Окт. 15, 2021

Lung epithelial and endothelial cell damage defective lung tissue repair contribute to fatal COVID-19.

Язык: Английский

Процитировано

202

Immune responses during COVID-19 infection DOI Creative Commons
Cléa Melenotte,

Aymeric Silvin,

Anne-Gaëlle Goubet

и другие.

OncoImmunology, Год журнала: 2020, Номер 9(1)

Опубликована: Янв. 1, 2020

Over the past 16 years, three coronaviruses (CoVs), severe acute respiratory syndrome CoV (SARS-CoV) in 2002, Middle East (MERS-CoV) 2012 and 2015, SARS-CoV-2 2020, have been causing fatal human epidemics. The unpredictability of coronavirus disease-19 (COVID-19) poses a major burden on health care economic systems across world. This is caused by paucity in-depth knowledge risk factors for COVID-19, insufficient diagnostic tools detection SARS-CoV-2, as well absence specific effective drug treatments. While protective humoral cellular immune responses are usually mounted against these betacoronaviruses, to SARS-CoV2 sometimes derail towards inflammatory tissue damage, leading rapid admissions intensive units. lack mechanisms that tilt balance between two opposite outcomes threats many ongoing clinical trials dealing with immunostimulatory or immunoregulatory therapeutics. review will discuss innate cognate underlying deleterious reactions pathogenic coronaviruses.

Язык: Английский

Процитировано

148

COVID-19 and the clinical course of rheumatic manifestations DOI Creative Commons
Sakir Ahmed, Olena Zimba, Armen Yuri Gasparyan

и другие.

Clinical Rheumatology, Год журнала: 2021, Номер 40(7), С. 2611 - 2619

Опубликована: Март 17, 2021

Язык: Английский

Процитировано

119

ACE2: the molecular doorway to SARS-CoV-2 DOI Creative Commons
Miriam Marlene Medina-Enríquez, Sandra López‐León, José Alberto Carlos-Escalante

и другие.

Cell & Bioscience, Год журнала: 2020, Номер 10(1)

Опубликована: Дек. 1, 2020

Abstract The angiotensin-converting enzyme 2 (ACE2) is the host functional receptor for new virus SARS-CoV-2 causing Coronavirus Disease 2019. ACE2 expressed in 72 different cell types. Some factors that can affect expression of are: sex, environment, comorbidities, medications (e.g. anti-hypertensives) and its interaction with other genes renin-angiotensin system pathways. Different risk infection determine severity symptoms. a negative regulator RAS various organ systems. It immunity, inflammation, increased coagulopathy, cardiovascular disease. In this review, we describe genetic molecular functions relation physiological pathological conditions to better understand how involved pathogenesis COVID-19. addition, it reviews comorbidities interact which also plays an important role. describes have influence activities receptor. goal provide reader understanding complexity importance

Язык: Английский

Процитировано

121

COVID-19 and thrombotic microangiopathies DOI Creative Commons
Nishant Tiwari, Sanat Phatak, Vivek R. Sharma

и другие.

Thrombosis Research, Год журнала: 2021, Номер 202, С. 191 - 198

Опубликована: Апрель 20, 2021

Severe COVID-19 can manifest as multiorgan dysfunction with pulmonary involvement being the most common and prominent. As more reports emerge in literature, it appears that an exaggerated immune response form of unfettered complement activation a cytokine storm may be key driver widespread organ injury seen this disease. In addition, these patients are also known to hypercoagulable high rate thrombosis higher-than-expected failure anticoagulation. While macrovascular is individuals, frequent finding extensive microvascular thromboses several series case reports, raises possibility thrombotic microangiopathy (TMA) contributing factor multi-organ complications If correct, rapidly identifying TMA treating underlying pathophysiology allow for better outcomes critically ill patients. To further explore this, we reviewed published literature on COVID-19, looking describing TMA-like presentations. We summarize our findings here along discussion about presentation, pathophysiology, suggested treatment algorithm.

Язык: Английский

Процитировано

82

Obesity and its impact on COVID-19 DOI Creative Commons

Angélica J. M. de Leeuw,

Maureen A. M. Oude Luttikhuis,

Annemarijn C. Wellen

и другие.

Journal of Molecular Medicine, Год журнала: 2021, Номер 99(7), С. 899 - 915

Опубликована: Апрель 6, 2021

Abstract The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic has proven a challenge to healthcare systems since its first appearance in late 2019. global spread and devastating effects of coronavirus disease 2019 (COVID-19) on patients have resulted countless studies risk factors progression. Overweight obesity emerged as one the major for developing COVID-19. Here we review biology infections relation obesity. In particular, literature about impact adiposity-related systemic inflammation COVID-19 severity, involving cytokine, chemokine, leptin, growth hormone signaling, discuss involvement hyperactivation renin-angiotensin-aldosterone system (RAAS). Due sheer number publications COVID-19, cannot be completed, therefore, apologize all that do not cite.

Язык: Английский

Процитировано

80

Anticoagulation in COVID-19: current concepts and controversies DOI Creative Commons
Atanu Chandra, Uddalak Chakraborty, Shrestha Ghosh

и другие.

Postgraduate Medical Journal, Год журнала: 2021, Номер 98(1159), С. 395 - 402

Опубликована: Апрель 13, 2021

Rising incidence of thromboembolism secondary to COVID-19 has become a global concern, with several surveys reporting increased mortality rates. Thrombogenic potential the SARS-CoV-2 virus been hypothesised originate from its ability produce an exaggerated inflammatory response leading endothelial dysfunction. Anticoagulants have remained primary modality treatment for decades. However, there is no universal consensus regarding timing, dosage and duration anticoagulation in as well need postdischarge prophylaxis. This article seeks review present guidelines recommendations ongoing trials on use anticoagulants COVID-19, identify discrepancies between all these, provide comprehensive strategy usage these drugs current pandemic.

Язык: Английский

Процитировано

74

Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States DOI Open Access

Rahul Raiker,

Charles DeYoung, Haig Pakhchanian

и другие.

Seminars in Arthritis and Rheumatism, Год журнала: 2021, Номер 51(5), С. 1057 - 1066

Опубликована: Авг. 20, 2021

Язык: Английский

Процитировано

73

Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19 DOI Creative Commons
Loes H. Willems, Magdolna Nagy, Hugo Ten Cate

и другие.

Thrombosis Research, Год журнала: 2021, Номер 209, С. 106 - 114

Опубликована: Дек. 4, 2021

Язык: Английский

Процитировано

72